Cocaine use disorder effects on blood oxytocin levels and OXTR DNA methylation
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
SOUZA, Manasses Soares
SANVICENTE-VIEIRA, Breno
ZAPARTE, Aline
BAPTISTA, Talita
VIOLA, Thiago Wendt
GRASSI-OLIVEIRA, Rodrigo
Citação
NEUROSCIENCE LETTERS, v.816, article ID 137506, 7p, 2023
Resumo
Substance use disorders have been associated with alterations in the oxytocinergic system, but few studies have investigated both the peptide and epigenetic mechanisms potentially implicated in the regulation of oxytocin receptor. In this study, we compared plasma oxytocin and blood DNA methylation in the OXTR gene between people with and without cocaine use disorder (CUD). We measured the oxytocin levels of 51 people with CUD during acute abstinence and of 30 healthy controls using an enzyme immunoassay. The levels of DNA methylation in four CpG sites at exon III of the OXTR gene were evaluated in a subsample using pyrosequencing. The Addiction Severity Index was used to assess clinical characteristics. We found higher oxytocin levels in men with CUD (56.5 pg/mL; 95% CI: 48.2-64.7) than in control men (33.6 pg/mL; 95% CI: 20.7-46.5), while no differences between women with and without CUD were detected. With a moderate effect size, the interaction effect between group and sex remained significant when controlling for height, weight and age data. A positive correlation in the CUD sample was found between oxytocin levels and days of psychological suffering prior to treatment enrollment. No group differences were observed regarding DNA methylation data. This suggests that CUD is associated with higher peripheral oxytocin levels in men during acute abstinence. This finding may be considered in future studies that aim at using exogenous oxytocin as a potential treatment for cocaine addiction.
Palavras-chave
Mechanism of addiction, Substance use disorders, Oxytocin levels, Oxytocinergic system, methylation DNA, Oxytocin receptor gene, Epigenetic
Referências
- Azadbakht A, 2022, EUR ADDICT RES, V28, P340, DOI 10.1159/000525443
- Baracz SJ, 2020, NEUROSCI BIOBEHAV R, V110, P114, DOI 10.1016/j.neubiorev.2018.08.014
- Bowen MT, 2017, TRENDS NEUROSCI, V40, P691, DOI 10.1016/j.tins.2017.10.003
- Carson DS, 2015, MOL PSYCHIATR, V20, P1085, DOI 10.1038/mp.2014.132
- Che XH, 2021, PHARMACOL THERAPEUT, V223, DOI 10.1016/j.pharmthera.2021.107820
- de Jong TR, 2015, PSYCHONEUROENDOCRINO, V62, P381, DOI 10.1016/j.psyneuen.2015.08.027
- Gerra LM, 2017, PROG NEURO-PSYCHOPH, V75, P70, DOI 10.1016/j.pnpbp.2017.01.005
- Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629
- Hidalgo-Figueroa M, 2022, INT J NEUROPSYCHOPH, V25, P666, DOI 10.1093/ijnp/pyac023
- Jirikowski Gustav F, 2018, Curr Top Behav Neurosci, V35, P77, DOI 10.1007/7854_2017_9
- Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038
- Kessler F, 2012, REV BRAS PSIQUIATR, V34, P24, DOI 10.1590/S1516-44462012000100006
- King CE, 2020, BRAIN RES, V1736, DOI 10.1016/j.brainres.2020.146761
- Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8
- Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
- Kubler U., 2013, Structured clinical interview for DSM-IV (SCID)
- Kumsta R, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00083
- Lenz B, 2021, EUR NEUROPSYCHOPHARM, V51, P55, DOI 10.1016/j.euroneuro.2021.04.015
- Lin SH, 2018, EUR ADDICT RES, V24, P71, DOI 10.1159/000485563
- McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
- MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006
- Melby K, 2022, HORM BEHAV, V146, DOI 10.1016/j.yhbeh.2022.105268
- Morgan MA, 1996, AM J OBSTET GYNECOL, V174, P1026, DOI 10.1016/S0002-9378(96)70344-7
- Nikolaou K, 2017, J PSYCHOACTIVE DRUGS, V49, P233, DOI 10.1080/02791072.2017.1312644
- Noel Raby W., 2022, Drug Alcohol Depend Rep, V2
- R Core Team, 2019, R: A language and environment for statistical computing
- Sanna F, 2021, CURR OPIN PHARMACOL, V58, P8, DOI 10.1016/j.coph.2021.03.002
- Shankman SA, 2018, INT J METH PSYCH RES, V27, DOI 10.1002/mpr.1590
- Shu C, 2022, DRUG ALCOHOL DEPEN, V235, DOI 10.1016/j.drugalcdep.2022.109431
- Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
- Strauss GP, 2015, SCHIZOPHR RES, V162, P47, DOI 10.1016/j.schres.2015.01.034
- Walum H, 2018, NAT REV NEUROSCI, V19, P643, DOI 10.1038/s41583-018-0072-6
- Yuen KW, 2014, J PSYCHIATR RES, V51, P30, DOI 10.1016/j.jpsychires.2013.12.012